COVID-19 may impact anatomy of retina and functional vision

News
Article

Choroidal and retinal changes were examined with optical coherence tomography angiography

An illustration of enlarged blood cells and a vial labeled "COVID-19." Image credit: ©Mongkolchon – stock.adobe.com

The decreased vascularity and perfusion, and the FAZ expansion, occurred during the acute phase of the infection, investigators reported. Image credit: ©Mongkolchon – stock.adobe.com

A new study from researchers in Turkey reported that during the acute phase of COVID-19 infection, the retinal vascularity and perfusion of the retina decreases and the foveal avascular zone (FAZ) expands.1

The authors, led by first author Kazim Kiratli, MD, suggested that the anatomy of the retina might be affected over time along with the functional vision. Kiratli is from the Department of Infectious Diseases and Clinical Microbiology, Katip Celebi University Ataturk Educating and Research Hospital, Izmir, Turkey.

Kiratli and colleagues explained that angiotensin-converting enzyme 2 (ACE2) is expressed in most bodily tissues and is the site by which the SARS virus enters the cells.2 It is already known that ACE2 receptors are located in the blood vessels, immune system, lungs, central nervous system, nose, cornea, conjunctiva and retina.3-5 Within the retina, ACE2 receptors are in the vascular endothelium, ganglion cells, muller glia and neurons in the inner nuclear layer,6 all of which provide a pathway for the virus.

This prospective case-control study included 85 patients with lung involvement related to the COVID-19 virus and a group of 50 healthy controls. Kiratli and colleagues measured the best-corrected visual acuity and intraocular pressure and evaluated the anterior and posterior segments in each participant. Optical coherence tomography angiography (OCTA) was performed in all participants. The choroidal and retinal changes were examined and recorded.

Measurement results

Compared with the healthy controls, the investigators did not find any significant changes in the choroidal thickness measurements in the COVID-19 group. Comparisons of the vascular densities and perfusion densities showed “a decrease in the averages of these values in the COVID-19 group, although [the differences were not] statistically significant (P =0.088, P =0.065 respectively). When the FAZ area values were compared, the average was 0.57±0.38 in the COVID-19 group, while it was 0.54±0.24 in the control group,” the authors reported.

Kiratli and colleagues pointed out that while significant differences in the measurements were not observed, the decreased vascularity and perfusion and the FAZ expansion occurred during the acute phase of the infection, ie, during the first month.

“These changes may anatomically alter the retina in the long term and affect the functional vision. Future ischemia-related alterations in the retina caused by a prior COVID-19 infection may arise in situations without comorbidities and may require concern in the patient’s systemic assessment," the authors said.

References

  1. Kiratli K, Kahraman HG, Guven, YZ, Akay F, .Aysin M. COVID-19’s effects on microvascular structure in a healthy retina: an OCTA study. Int J Ophthalmol. 2025;2:283-289; doi: 10.18240/ijo.2025.02.12
  2. Hoffmann M, Kleine-Weber H, Schroeder S, et al. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell. 2020;181:271-280.e8.
  3. Hamming I, Timens W, Bulthuis ML, et al. Tissue distribution of ACE2 protein, the functional receptor for SARS coronavirus. A first step in understanding SARS pathogenesis. J Pathol. 2004;203:631-637.
  4. Lange C, Wolf J, Auw-Haedrich C, et al. Expression of the COVID-19 receptor ACE2 in the human conjunctiva. J Med Virol. 2020;92:2081-2086.
  5. Senanayake PD, Drazba J, Shadrach K, et al. Angiotensin II and its receptor subtypes in the human retina. Invest Ophthalmol Vis Sci. 2007;48:3301-3311.
  6. Choudhary R, Kapoor MS, Singh A, et al. Therapeutic targets of renin-angiotensin system in ocular disorders. J Curr Ophthalmol. 2017;29:7-16.

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
Christine Curcio, PhD, of the University of Alabama at Birmingham Heersink School of Medicine, shares histology update and revised nomenclature for OCT with Sheryl Stevenson of the Eye Care Network and Ophthalmology Times
SriniVas R. Sadda, MD, FARVO, shares key points from his retina presentation at the International SPECTRALIS Symposium
Robert Sergott, MD, describes fluorescence lifetime imaging ophthalmoscopy (FLIO) and the International SPECTRALIS Symposium – And Beyond (ISS) in Heidelberg, Germany.
Rayaz Malik, MBChB, PhD, a professor of medicine at Weill Cornell Medicine - Qatar, spoke with Ophthalmology Times Europe about his presentation. It's titled "An eye on neurodegenerative diseases: Challenging the dogma" at the International SPECTRALIS Sympsoium. In conversation with Hattie Hayes, Ophthalmology Times Europe
Anat Loewenstein, MD, describes her presentation on remote imaging for age-related macular degeneration and geographic atrophy at the International SPECTRALIS Symposium, in conversation with Hattie Hayes of Ophthalmology Times Europe
Tyson Brunstetter, OD, PhD, a US Navy Aerospace Optometrist at the NASA Johnson Space Center in Houston, Texas, shares key takeaways from his keynote at the International SPECTRALIS Symposium (ISS)
Rayaz Malik, MBChB, PhD, shares his presentation, titled An eye on neurodegenerative diseases: Challenging the dogma, at this year's International SPECTRALIS Symposium
At the Retina World Congress, Siegfried Priglinger, MD, speaks about ensuring the best outcomes for preschool-aged patients
At the 2025 ASCRS meeting, Robert Ang, MD said small aperture IOLs can benefit all patients, especially those with complex corneas or who have undergone previous corneal refractive surgery
Viha Vig, MBChB graduate student at the University of Auckland, New Zealand, discusses her poster presentation on the relationship between mitochondiral disease, Alzheimer disease, and other types of dementia.
Related Content
© 2025 MJH Life Sciences

All rights reserved.